Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A retrospective real world study.

被引：1
|
作者：
Chen, Yang
Dai, Guanghai
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience
    Al-Shamsi, Humaid O.
    Fahmawi, Yazan
    Dahbour, Ibrahim
    Tabash, Aziz
    Rogers, Jane E.
    Mares, Jeannette Elizabeth
    Blum, Mariela A.
    Estrella, Jeannelyn
    Matamoros, Aurelio, Jr.
    Sagebiel, Tara
    Devine, Catherine E.
    Badgwell, Brian D.
    Lin, Quan D.
    Das, Prajnan
    Ajani, Jaffer A.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (04) : 499 - 505
  • [22] Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
    Porth, Isabel
    Hirsch, Daniela
    Ceribas, Yonca
    Weidner, Philip
    Weichert, Wilko
    Goetze, Thorsten Oliver
    Perner, Sven
    Luley, Kim
    Heyer, Christian Moritz
    de la Torre, Carolina
    Hofheinz, Ralf-Dieter
    Lorenzen, Sylvie
    Gaiser, Timo
    EUROPEAN JOURNAL OF CANCER, 2023, 183 : 119 - 130
  • [23] Trastuzumab: A Review of Its Use in HER2-Positive Advanced Gastric Cancer
    Mark Sanford
    Drugs, 2013, 73 : 1605 - 1615
  • [24] Trastuzumab: A Review of Its Use in HER2-Positive Advanced Gastric Cancer
    Sanford, Mark
    DRUGS, 2013, 73 (14) : 1605 - 1615
  • [25] The efficacy and safety of trastuzumab for unresectable advanced HER2-positive gastric cancer
    Matsueda, Katsunori
    Toyokawa, Tatsuya
    Horii, Joichiro
    Fujita, Isao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 95 - 95
  • [26] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Pamuk, Aylin
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 74 - 76
  • [27] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [28] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
    Kotani, Daisuke
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [29] Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study *
    Frydman, Anne-Esther
    Drouillard, Antoine
    Soularue, Emilie
    Dubreuil, Olivier
    Zaanan, Aziz
    Turpin, Anthony
    Tougeron, David
    Doat, Solene
    Bachet, Jean -Baptiste
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 198 - 205
  • [30] SURVIVAL OF PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER (ABC) NOT CONTINUING TRASTUZUMAB (T) BEYOND DISEASE PROGRESSION AFTER DOCETAXEL (D) AND TRASTUZUMAB
    Montemurro, Filippo
    Faggiuolo, Roberto
    Donadio, Michela
    Redana, Stefania
    Minischetti, Monica
    Durando, Antonio
    Buosi, Roberta
    Vietti-Ramus, Guido
    Aglietta, Massimo
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
12345